The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
Key takeaways of recent quarter & conference call highlights
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care
Subscribe To Our Newsletter & Stay Updated
